Even in a year of unprecedented challenges, there are powerful reasons for hope in cervical cancer prevention.
As of 2025, nearly 150 countries (~76% of WHO members) have introduced HPV vaccination, with 51% now using gender-neutral programs for boys and girls. Evidence-based and a highly effective single-dose schedule is being widely adopted globally following WHO guidance.
Cervical cancer self-sampling is also expanding worldwide beyond just reaching “hard to reach” groups, with ~17 countries already adopting it in their national programs. In the U.S., the FDA approved in-clinic self-collection (2024), the American Cancer Society endorsed self-collected HPV testing (2025), and the Teal Wand at-home test followed with a nationwide rollout expected in 2026 – advancing access, privacy, equity, patient empowerment, and participation.
Join us for the 8th Annual Us vs. HPV Prevention Week
Theme: Building Community Around HPV Prevention and Related Disease Management
January 26–30, 2026
Hosted by AMWA and GIAHC (Registration will also enable access to on-demand recordings)
- International Day Webinar – Wednesday, January 28, 2026
- Hope, Hurdles and the Way Forward: The Global Drive to End Cervical Cancer
- 10:00–11:15 AM EST (to accommodate a wider global audience)
This session will celebrate U.S. and global progress, highlight policy and scientific advances, and explore exciting developments on the horizon.
Featured Speakers: Kathy Castor, Anna Giuliano, Zainab Bagudu, Mridu Gupta, Mauricio Maza, Kathleen Schmeler, Catharine Young
Who should attend:
- Healthcare professionals, advocates, patients, young leaders, policymakers, community influencers, caregivers, and anyone passionate about HPV and cancer prevention.
Let’s end the very first cancer – TOGETHER!
You can also join us at the OncoDaily Cervical Cancer Summit 2026 as we advance collaboration, innovation, and impact.
